The p160 nuclear receptor co-activators represent a family of molecules, which are recruited by steroid nuclear receptors as well as other transcription factors that are overexpressed in several tumors. We investigated the role of one member of this family on the sensitivity of cells to apoptosis. We observed that overexpression of the RAC3 (receptor-associated co-activator-3) p160 co-activator inhibits hydrogen peroxide-induced cell death in human embryonic kidney 293 (HEK293) cells. The mechanism involves the activation of anti-apoptotic pathways mediated through enhanced nuclear factor kappa B (NFjB) activity, inhibition of caspase-9 activation, diminished apoptotic-inducing factor (AIF) nuclear localization and a change in the activation pattern of several kinases, including an increase in both AKT and p38 kinase activities, and inhibition of ERK2. Moreover, RAC3 has been found associated with a protein complex containing AIF, Hsp90 and dynein, suggesting a role for the coactivator in the cytoplasmatic nuclear transport of these proteins associated with cytoskeleton. These results demonstrate that there are several molecular pathways that could be affected by their overexpression, including those not restricted to steroid regulation or the nuclear action of co-activators, which results in diminished sensitivity to apoptosis. Furthermore, this could represent one mechanism by which co-activators contribute to tumor development.
RAC3 is an oncogene naturally overexpressed in several tumors. Besides its role as coactivator, it can exert several protumoral cytoplasmic actions. Autophagy was found to act either as a tumor suppressor during the early stages of tumor development, or as a protector of the tumor cell in later stages under hypoxic conditions. We found that RAC3 overexpression inhibits autophagy when induced by starvation or rapamycin and involves RAC3 nuclear translocation-dependent and -independent mechanisms. Moreover, hypoxia inhibits the RAC3 gene expression leading to the autophagy process, allowing tumor cells to survive until angiogenesis occurs. The interplay between RAC3, hypoxia, and autophagy could be an important mechanism for tumor progression and a good target for a future anticancer therapy. (Cancer Sci 2012; 103: 2064-2071 A utophagy is a highly regulated cellular process that serves to remove damaged proteins and organelles from the cell. It contributes to an array of normal and pathological processes, and has recently emerged as a key regulator of multiple aspects of cancer biology.Autophagy is not only triggered under nutrient deficiency, resulting in mTOR pathway inhibition, but also under cellular stress, or mitochondria or endoplasmic reticulum damage.(1) Several transcription factors can also induce autophagy, such as HIF-a and FoxoA1, which are involved in hypoxia and aging responses, respectively.(1) Autophagy and nuclear factorkappa B (NF-jB) share common signals and regulators; both are able to control each other through positive or negative feedback loops, thus ensuring homeostatic responses.(2) Moreover, kinases were also found to have positive or negative modulation on autophagy. Class I phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) (both involved in the mTOR pathway), p70S6K, and p38 (3) were associated with inhibitory effects, whereas ERK, death-associated protein kinase, and c-Jun N-terminal kinase were involved in positive modulation of autophagy. (4) The molecular mechanism by which autophagy takes place is complex and implicates several steps.(5) Interference at initiation could lead to the complete inhibition of autophagy, and blockage on maturation could result in an abnormal accumulation of immature autophagosomes.(6) In normal cells, these two scenarios could be pathological. However, the role of autophagy in cancer is not at all clear and is likely dependent on tumor type, stage, and genetic context. This complexity is illustrated by the fact that autophagy has a dual effect in tumorigenesis, either inhibiting it during the early stages or promoting it at later stages or during chemotherapy (5) in order to allow tumor maintenance.The gene RAC3 (AIB1, SRC-3, NCoA3) is a member of the nuclear receptor coactivator p160 family, together with SRC-1 and TIF-2.(7,8) Although it was first described as a coactivator of estrogen receptor and other steroid receptors, (8) we have previously found that RAC3 is also a NF-jB coactivator.(9) In any case, it has an intrinsic histone ace...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.